Stockscreener 앱 받기
317.25
6.55%
19.51
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines stock hits 52-week high at $318.24 By Investing.com - Investing.com Nigeria
Behavioral Patterns of PRAX and Institutional Flows - Stock Traders Daily
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus - Insider Monkey
Aug PreEarnings: Can Praxis Precision Medicines Inc outperform in the next rallyPortfolio Value Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom - TechStock²
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 7%Here's Why - MarketBeat
Praxis Precision Medicines (PRAX) Price Target Increased by 14.92% to 471.78 - Nasdaq
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy - PharmiWeb.com
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Buyout Rumor: Can Praxis Precision Medicines Inc deliver consistent dividendsJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy - Quiver Quantitative
Praxis Precision Medicines Appoints Orrin Devinsky as Head of Clinical Strategy - marketscreener.com
US Biotech Share Sales Deliver Biggest First Week Since 2021 - Bloomberg.com
Praxis Precision Medicines plans two NDA submissions by mid-February - Investing.com Nigeria
PRAX Stock Price, Forecast & Analysis | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - Chartmill
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.1%Here's Why - MarketBeat
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress - Investing News Network
Praxis Precision Medicines (PRAX) Sets Ambitious Targets for 202 - GuruFocus
PRAX: Wedbush Raises Price Target Despite "Underperform" Rating - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Two new brain disorder drugs head to FDA as Praxis nears key 2026 data - Stock Titan
Needham analyst keeps a buy rating on Praxis Precision Medicines, Inc. (PRAX) - MSN
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) - Insider Monkey
20 Best Performing Stocks in 2025 - Insider Monkey
Will Praxis Precision Medicines Inc. stock see PE expansionPerformance Line Overview & quick comparison of popular models - ulpravda.ru
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biopharmaceutical company uses stock grants to attract three new employees - Stock Titan
How Praxis’s Big Equity Raise, Ulixacaltamide Breakthrough Status And Board Shake-Up At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story - Sahm
Praxis Precision (PRAX) Announces Key Leadership Changes - GuruFocus
Praxis Precision Medicines appoints new board members, promotes executives By Investing.com - Investing.com India
Praxis Precision Medicines appoints new board members, promotes executives - Investing.com
Praxis Precision Medicines Announces Key Management Appointments - TradingView — Track All Markets
Praxis Precision Medicines Announces New Board Appointments and Executive Promotions to Drive Growth and Commercial Readiness - Quiver Quantitative
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - Chartmill
Will Praxis Precision Medicines Inc. stock reach all time highs in 2025 - ulpravda.ru
How strong is Praxis Precision Medicines Inc. stock balance sheet2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
Will Praxis Precision Medicines Inc. stock benefit from commodity pricesJuly 2025 Volume & Real-Time Market Sentiment Alerts - ulpravda.ru
S P Trends: Is Praxis Precision Medicines Inc. stock a smart buy before Fed meeting2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a smart buy before Fed meetingJuly 2025 Selloffs & Real-Time Stock Movement Alerts - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a buy in volatile marketsJuly 2025 EndofMonth & Capital Efficient Trade Techniques - ulpravda.ru
New leadership steps in as Praxis prepares for potential brain drug launches - Stock Titan
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
PRAX Stock Surge: Time to Buy? - StocksToTrade
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Praxis Precision Medicines Announces Major Underwritten Equity Offering - TipRanks
Praxis Precision Medicines Announces Underwritten Offering - TradingView — Track All Markets
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 8.2%What's Next? - MarketBeat
Praxis Precision Medicines (PRAX) Valuation Check After A Strong 90 Day Share Price Run - Yahoo Finance
Praxis Precision stock rises as $575 million share sale clears at $260 - TechStock²
Praxis Precision Medicines edges down after $575 mln stock sale - TradingView — Track All Markets
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $207,000 Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):